Tokyo Tape
Sign in
← Koa Shoji Holdings

Quarterly report · Q3

9273.TEDINET S100TEGN
Period2023-07-01 → 2024-03-31
Filed2024-05-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥16.8bn2023-07-01 → 2024-03-31Cons.Net sales
Revenue¥22.1bn2022-07-01 → 2023-06-30Cons.Net sales (5-year summary)
Revenue¥16.2bn2022-07-01 → 2023-03-31Cons.Net sales
Operating income¥3.6bn2023-07-01 → 2024-03-31Cons.Operating income
Operating income¥3.3bn2022-07-01 → 2023-03-31Cons.Operating income
Ordinary income¥3.6bn2023-07-01 → 2024-03-31Cons.Ordinary income
Ordinary income¥4.1bn2022-07-01 → 2023-06-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥3.2bn2022-07-01 → 2023-03-31Cons.Ordinary income
Profit before tax¥3.6bn2023-07-01 → 2024-03-31Cons.Income before income taxes
Profit before tax¥3.2bn2022-07-01 → 2023-03-31Cons.Income before income taxes
Net income (owners)¥2.3bn2023-07-01 → 2024-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.7bn2022-07-01 → 2023-06-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.1bn2022-07-01 → 2023-03-31Cons.Profit loss attributable to owners of parent
Net income¥2.3bn2023-07-01 → 2024-03-31Cons.Profit loss
Net income¥2.1bn2022-07-01 → 2023-03-31Cons.Profit loss
Total assets¥30.0bnat 2024-03-31Cons.Assets
Total assets¥28.5bnat 2023-06-30Cons.Assets
Total assets¥27.5bnat 2023-03-31Cons.Total assets (5-year summary)
Total liabilities¥7.3bnat 2024-03-31Cons.Liabilities
Total liabilities¥7.5bnat 2023-06-30Cons.Liabilities
Net assets / equity¥22.7bnat 2024-03-31Cons.Net assets
Net assets / equity¥20.9bnat 2023-06-30Cons.Net assets
Net assets / equity¥20.3bnat 2023-03-31Cons.Net assets (5-year summary)
Cash and deposits¥10.7bnat 2024-03-31Cons.Cash and deposits
Cash and deposits¥10.8bnat 2023-06-30Cons.Cash and deposits
EPS (basic)¥57.12023-07-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥17.642024-01-01 → 2024-03-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥67.832022-07-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥52.482022-07-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥17.292023-01-01 → 2023-03-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio75.7%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio73.5%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio73.7%at 2023-03-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 28
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-07-01 → 2024-03-31−¥1.3bn
Reconciling Itemsreconcilingrevenue intersegment2023-07-01 → 2024-03-31−¥1.3bn
Reconciling Itemsreconcilingsegment profit2023-07-01 → 2024-03-31−¥11m
jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segmentrevenue2023-07-01 → 2024-03-31¥11.5bn
jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segmentrevenue external2023-07-01 → 2024-03-31¥10.3bn
jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segmentrevenue intersegment2023-07-01 → 2024-03-31¥1.3bn
jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segmentsegment profit2023-07-01 → 2024-03-31¥2.1bn
jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue2023-07-01 → 2024-03-31¥6.5bn
jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue external2023-07-01 → 2024-03-31¥6.5bn
jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segmentsegment profit2023-07-01 → 2024-03-31¥1.5bn
—segment totalrevenue2023-07-01 → 2024-03-31¥18.0bn
—segment totalrevenue external2023-07-01 → 2024-03-31¥16.8bn
—segment totalrevenue intersegment2023-07-01 → 2024-03-31¥1.3bn
—segment totalsegment profit2023-07-01 → 2024-03-31¥3.6bn
Reconciling Itemsreconcilingrevenue2022-07-01 → 2023-03-31−¥1.4bn
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2023-03-31−¥1.4bn
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2023-03-31¥16m
jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segmentrevenue2022-07-01 → 2023-03-31¥11.5bn
jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segmentrevenue external2022-07-01 → 2023-03-31¥10.2bn
jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segmentrevenue intersegment2022-07-01 → 2023-03-31¥1.4bn
jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segmentsegment profit2022-07-01 → 2023-03-31¥2.0bn
jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue2022-07-01 → 2023-03-31¥6.0bn
jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue external2022-07-01 → 2023-03-31¥6.0bn
jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segmentsegment profit2022-07-01 → 2023-03-31¥1.2bn
—segment totalrevenue2022-07-01 → 2023-03-31¥17.5bn
—segment totalrevenue external2022-07-01 → 2023-03-31¥16.2bn
—segment totalrevenue intersegment2022-07-01 → 2023-03-31¥1.4bn
—segment totalsegment profit2022-07-01 → 2023-03-31¥3.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 356
ItemContextValueUnit
Investment securitiesPrior1YearInstant56775000JPY
Investment securitiesCurrentQuarterInstant93855000JPY
Deferred tax assetsPrior1YearInstant222079000JPY
Deferred tax assetsCurrentQuarterInstant205303000JPY
Net defined benefit assetPrior1YearInstant29891000JPY
Net defined benefit assetCurrentQuarterInstant22092000JPY
Other ioaPrior1YearInstant15652000JPY
Other ioaCurrentQuarterInstant12591000JPY
Investments and other assetsPrior1YearInstant324399000JPY
Investments and other assetsCurrentQuarterInstant333843000JPY
Noncurrent assetsPrior1YearInstant6634234000JPY
Noncurrent assetsCurrentQuarterInstant7304420000JPY
AssetsPrior1YearInstant28464493000JPY
AssetsCurrentQuarterInstant30002458000JPY
Notes and accounts payable tradePrior1YearInstant1504004000JPY
Notes and accounts payable tradeCurrentQuarterInstant1542636000JPY
Electronically recorded obligations operating clPrior1YearInstant686818000JPY
Electronically recorded obligations operating clCurrentQuarterInstant692347000JPY
Short term loans payablePrior1YearInstant850000000JPY
Short term loans payableCurrentQuarterInstant850000000JPY
Current portion of long term loans payablePrior1YearInstant349904000JPY
Current portion of long term loans payableCurrentQuarterInstant373904000JPY
Income taxes payablePrior1YearInstant810011000JPY
Income taxes payableCurrentQuarterInstant567064000JPY
Provision for bonusesPrior1YearInstant48558000JPY
Provision for bonusesCurrentQuarterInstant85049000JPY
Other clPrior1YearInstant984618000JPY
Other clCurrentQuarterInstant1080515000JPY
Current liabilitiesPrior1YearInstant5233914000JPY
Current liabilitiesCurrentQuarterInstant5191517000JPY
Long term loans payablePrior1YearInstant1941288000JPY
Long term loans payableCurrentQuarterInstant1704336000JPY
Deferred tax liabilitiesPrior1YearInstant1460000JPY
Deferred tax liabilitiesCurrentQuarterInstant2553000JPY
Provision for directors retirement benefitsPrior1YearInstant137624000JPY
Provision for directors retirement benefitsCurrentQuarterInstant147640000JPY
Net defined benefit liabilityPrior1YearInstant135597000JPY
Net defined benefit liabilityCurrentQuarterInstant151143000JPY
Other nclPrior1YearInstant91119000JPY
Other nclCurrentQuarterInstant82871000JPY
Noncurrent liabilitiesPrior1YearInstant2307090000JPY
Noncurrent liabilitiesCurrentQuarterInstant2088545000JPY
LiabilitiesPrior1YearInstant7541004000JPY
LiabilitiesCurrentQuarterInstant7280062000JPY
Capital stockPrior1YearInstant522277000JPY
Capital stockCurrentQuarterInstant522277000JPY
Capital surplusPrior1YearInstant205828000JPY
Capital surplusCurrentQuarterInstant205828000JPY
Retained earningsPrior1YearInstant20172089000JPY
Retained earningsCurrentQuarterInstant21958961000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-06-30pass rounding
balance sheet identityconsolidated 2024-03-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2024-03-31pass
statement vs summary · revenueconsolidated 2022-07-01/2023-03-31pass
statement vs summary · revenueconsolidated 2023-07-01/2024-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass